Navigation Links
AVEO Pharmaceuticals Novel Oncology Research Platform and Clinical,Pipeline to Be Featured at AACR

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr 12, 2007 - AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on the discovery and development of novel, targeted cancer medicines, announced today that it will present a total of 12 oral and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting on April 14-18, 2007, in Los Angeles, California.

"We are very excited to share with the cancer community the pioneering oncology research platform AVEO has developed, which we believe may significantly enhance the probability of success and the efficacy of the next generation of targeted cancer therapies," said Tuan Ha-Ngoc, president and CEO of AVEO Pharmaceuticals. "AVEO is focusing on translating this groundbreaking science into new drugs that may have a significant impact on cancer patient care and more importantly, patient response and outcomes."

These presentations focus on several applications of AVEO's breakthrough Human Response Prediction(TM) Platform of in vivo inducible mouse models.

The abstracts selected for oral presentations at the AACR Annual Meeting are listed below:

-- Saturday, April 14, 2007 at 9:00 a.m. to 9:20 a.m. "Response prediction in engineered models: Using natural variation in preclinical tumor populations to assess the genetic context of drug response" - Educational Session: Validating Therapeutic Targets: In Vivo Models and Clinical Responses - Concourse E

-- Saturday, April 14, 2007 at 2:00 p.m. to 2:20 p.m. "Human-in-mouse tumors: Creating de novo human breast cancer in mice through ex vivo genetic manipulation of normal breast tissue" - Methods Workshop: Recent Advances in Mouse Models of Cancer - Concourse E

-- Wednesday, April 18, 2007 at 10:40 a.m. to 10:55 a.m. "Comprehensive in vivo genetic screens for tumor maintenance pathways in solid tumor models by retroviral mutagenesis" - Mini-symposium: Integrated Ge nomic Analysis of Human Cancer - Room 304 A-C

-- Wednesday, April 18, 2007 at 10:25 a.m. to 10:40 a.m. "A novel chimeric approach to modeling cancer in mice reveals that EGFR dependency in lung tumors is mediated through non canonical RTK-MAPK signaling" - Mini-symposium: Mouse Models of Cancer - Room 406 A-B

-- Wednesday, April 18, 2007 at 10:40 a.m. to 10:55 a.m. "Genetically engineered human breast cancer in mouse (HIM): A novel cancer model system that progresses in vivo and exhibits phenotypic variations" - Mini-symposium: Mouse Models of Cancer - Room 406 A-B

The schedule for poster presentations at the AACR Annual Meeting is listed below:

-- Monday, April 16, 2007 at 8:00 a.m. to 12:00 p.m. "Genetically engineered murine tumor models for drug response prediction: Population based pathway profiles predict response to repamycin in a HER2 driven breast model" - Poster Session: Mouse Models in Cancer - Section 23, Board 28

-- Monday, April 16, 2007 at 1:00 p.m. to 5:00 p.m. "Directed complementation of inducible tumor models: An approach to generate broad panels of tumors with defined genetic contexts" - Poster Session: Mouse Models of Cancer - Section 22, Board 29

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "AV-412, a potent EGFR/HER2 TK inhibitor causes tumor regression in novel genetically engineered EGFRL858R and EGFRL858R and T790M lung tumor models" - Poster Session: EGFR Inhibition - Section 28, Board 6

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "A novel beta-Catenin dependent p53DN mouse model of colon cancer displays stage dependent expression of EGFR" - Poster Session: Mouse Models of Cancer - Section 20, Board 9

-- Tuesday, April 17, 2007 at 8:00 a.m. to 12:00 p.m. "A chimeric mouse model of ovarian cancer driven by inducible expression of PI3K catalytic subunit (p110alpha)" - Poster Session: Mouse Models of Cancer - Section 21, Board 4

-- Tuesday, April 17, 2007 at 8:0 0 a.m. to 12:00 p.m. "Novel human basal type breast cancer models generated through genetic manipulation of normal human breast tissue in mice" - Poster Session: Mouse Models of Cancer - Section 21, Board 8

-- Tuesday, April 17, 2007 at 1:00 p.m. to 5:00 p.m. "In vivo genetic screens designed to complement loss of HER2 of kRas functions identify c-Met/HGF pathway as potent driver of growth/survival in solid tumor models" - Poster Session: Mouse Models of Cancer - Section 21, Board 8

About AVEO

AVEO is a private biopharmaceutical company focused on the discovery and development of novel, targeted cancer therapeutics. The company utilizes its proprietary, genetically-defined cancer models for the identification and validation of novel cancer targets, and has begun to build an impressive portfolio of drug discovery and development programs around these high-value targets. AVEO also uses its Human Response Prediction(TM) Platform to identify genetic profiles that correspond with patient responsiveness. AVEO expects to commence Phase 2 clinical studies by mid-2007 for AV-951, its oral, second-generation VEGF receptor inhibitor and most advanced clinical program. AV-412, AVEO's EGFR/HER2 inhibitor, is currently in Phase I clinical trials. AV-299, a novel anti-HGF mAb, is currently being manufactured by XOMA under a supply agreement in anticipation of entering the clinic in early 2008. AVEO is located in Cambridge, Massachusetts. For more information, please visit the company's website at www.aveopharma.com.

Contact

AVEO Pharmaceuticals, Inc.
JJ Owen, PhD, Manager, Business Development
jjowen@aveopharma.com, 617-299-5889
or
Pure Communications
Adriana Jenkins, 617-744-1713


'"/>




Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... startling report released today, National Safety Council research shows ... plan to eliminate prescription opioid overdoses. Prescription Nation ... the worst drug crisis in recorded U.S. history, assigned a "Making ... , New Mexico , Tennessee ... states, three – Michigan , Missouri ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily customize ... Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures into ... Simply select a ProHand generator and drag it above media or text in the ...
(Date:6/25/2016)... , ... June 25, 2016 , ... ... and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as a ... area —Johnson is one of the first doctors to perform the treatment. Orthobiologics ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... a crisis. Her son James, eight, was out of control. Prone to extreme mood shifts ... upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a knife ... and say he was going to kill them. If we were driving on the ...
(Date:6/24/2016)... ... June 24, 2016 , ... Dr. Amanda Cheng, an ... Dr. Cheng has extensive experience with all areas of orthodontics, including robotic Suresmile ... orthodontics. , Micro-osteoperforation is a revolutionary adjunct to orthodontic treatment. It can ...
Breaking Medicine News(10 mins):